Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 65 citing articles:

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani, et al.
The Lancet (2023) Vol. 403, Iss. 10424, pp. 379-390
Open Access | Times Cited: 63
Aldosterone in chronic kidney disease and renal outcomes
Ashish Verma, Anand Vaidya, Sonu Subudhi, et al.
European Heart Journal (2022) Vol. 43, Iss. 38, pp. 3781-3791
Open Access | Times Cited: 55
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms
Murray Epstein, Csaba P. Kövesdy, Catherine M. Clase, et al.
American Journal of Kidney Diseases (2022) Vol. 80, Iss. 5, pp. 658-666
Open Access | Times Cited: 47
Cardiorenal benefits of finerenone: protecting kidney and heart
José Ramón González–Juanatey, José Luis Górriz, Alberto Ortíz, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1, pp. 502-513
Open Access | Times Cited: 31
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Dong‐Lim Kim, Seung‐Eun Lee, Nan Hee Kim
Endocrinology and Metabolism (2023) Vol. 38, Iss. 1, pp. 43-55
Open Access | Times Cited: 27
Edema formation in congestive heart failure and the underlying mechanisms
Zaid Abassi, Emad E. Khoury, Tony Karram, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 35
Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Mingzhu Zhang, Wujisiguleng Bao, Qiyan Zheng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 27
Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study
Yu Li, Jiaxing Feng, Xiaodan Guo, et al.
Research Square (Research Square) (2025)
Closed Access
Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers
Friedrich Schulze, Jennifer Schaible, Markus Goettel, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors/SGLT-2i
Ruoqi Liu, Zhi Qu, Yun‐Zhi Feng, et al.
Journal of Diabetes and its Complications (2025) Vol. 39, Iss. 4, pp. 108981-108981
Closed Access
Fgf23 expression increases atherosclerotic plaque burden in male ApoE deficient mice
Karolina Lindberg, О. А. Овчинникова, Matthias B. Moor, et al.
Atherosclerosis (2025) Vol. 403, pp. 119158-119158
Open Access
Evidence for the use of a nonsteroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease
Mariana Morais David Pliças, Bernardo Marques da Silva, Edgar Almeida
Nefrología (English Edition) (2025) Vol. 45, Iss. 3, pp. 214-227
Open Access
Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease
Edgar V. Lerma, William B. White, George L. Bakris
Postgraduate Medicine (2022) Vol. 135, Iss. 3, pp. 224-233
Open Access | Times Cited: 20
Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys
Jordana B. Cohen, Irina Bancos, Jenifer M. Brown, et al.
Annual Review of Medicine (2022) Vol. 74, Iss. 1, pp. 217-230
Open Access | Times Cited: 18
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Nina Hojs, Sebastjan Bevc, Robert Ekart, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 6, pp. 561-561
Open Access | Times Cited: 21
Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes
David S.H. Bell, Janet B. McGill, Terri Jerkins
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 2795-2804
Open Access | Times Cited: 7
Licorice metabolite 18β‐glycyrrhetinic acid activates G protein‐gated inwardly rectifying K+ channels
I‐Shan Chen, Jumpei Yasuda, Takuya Notomi, et al.
British Journal of Pharmacology (2023) Vol. 181, Iss. 3, pp. 447-463
Closed Access | Times Cited: 7
From inflammation to renal fibrosis: A one-way road in autoimmunity?
Dario Roccatello, Hui Y. Lan, Savino Sciascia, et al.
Autoimmunity Reviews (2023) Vol. 23, Iss. 4, pp. 103466-103466
Closed Access | Times Cited: 7
Decoding the role of aldosterone in glycation-induced diabetic complications
Mayura M. Apte, Saee Zambre, Pratiksha Pisar, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 721, pp. 150107-150107
Closed Access | Times Cited: 2
AIM2 inflammasome contributes to aldosterone-induced renal injury via endoplasmic reticulum stress
Yong Wu, Huan Yang, Sujuan Xu, et al.
Clinical Science (2021) Vol. 136, Iss. 1, pp. 103-120
Open Access | Times Cited: 17
Mechanisms of current therapeutic strategies for heart failure: more questions than answers?
Muhammad Shahzeb Khan, Izza Shahid, Stephen J. Greene, et al.
Cardiovascular Research (2022) Vol. 118, Iss. 18, pp. 3467-3481
Open Access | Times Cited: 9
Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease
José Luis Górriz, José Ramón González–Juanatey, Lorenzo Fácila, et al.
Nefrología (English Edition) (2023) Vol. 43, Iss. 4, pp. 386-398
Open Access | Times Cited: 5
Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases
Wen‐Ming Chen, Lingqian Zheng, Jiali Wang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 5
Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: an extraordinary paradigm shift
Murray Epstein
Kidney International Supplements (2022) Vol. 12, Iss. 1, pp. 1-6
Open Access | Times Cited: 8
Fgf23 expression increases atherosclerotic plaque burden in male ApoE deficient mice
Karolina Lindberg, О. А. Овчинникова, Matthias B. Moor, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top